drugset / Trial / NCT03367572
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
Phase 3
Completed
1363 enrolled
University of Rochester NCORP Research Base
National Cancer Institute (NCI) · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.
Timeline
- Start
- 2018-04-19
- Primary completion
- 2024-04-13
- Completion
- 2024-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olanzapine | Small molecule | — | Oral |
| Subject | Prochlorperazine | Small molecule | — | Oral |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Netupitant/Palonosetron Hydrochloride | Unknown | — | Oral |